IMTX vs. AGEN, NVAX, JATT, HLVX, FDMT, FATE, EDIT, ALEC, CHRS, and SRRK
Should you be buying Immatics stock or one of its competitors? The main competitors of Immatics include Agenus (AGEN), Novavax (NVAX), JATT Acquisition (JATT), HilleVax (HLVX), 4D Molecular Therapeutics (FDMT), Fate Therapeutics (FATE), Editas Medicine (EDIT), Alector (ALEC), Coherus BioSciences (CHRS), and Scholar Rock (SRRK). These companies are all part of the "biological products, except diagnostic" industry.
Immatics vs.
Immatics (NASDAQ:IMTX) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability.
Immatics has higher earnings, but lower revenue than Agenus. Agenus is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.
Immatics has a net margin of 24.60% compared to Agenus' net margin of -235.30%. Immatics' return on equity of 40.49% beat Agenus' return on equity.
Agenus received 435 more outperform votes than Immatics when rated by MarketBeat users. However, 70.97% of users gave Immatics an outperform vote while only 70.52% of users gave Agenus an outperform vote.
29.1% of Immatics shares are owned by institutional investors. Comparatively, 53.8% of Agenus shares are owned by institutional investors. 4.8% of Agenus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Agenus had 18 more articles in the media than Immatics. MarketBeat recorded 25 mentions for Agenus and 7 mentions for Immatics. Immatics' average media sentiment score of 0.30 beat Agenus' score of 0.24 indicating that Immatics is being referred to more favorably in the media.
Immatics presently has a consensus target price of $27.00, suggesting a potential upside of 285.71%. Agenus has a consensus target price of $7.10, suggesting a potential upside of 367.11%. Given Agenus' higher possible upside, analysts plainly believe Agenus is more favorable than Immatics.
Immatics has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Agenus has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.
Summary
Immatics beats Agenus on 9 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Immatics Competitors List